Bitcoin Might Revisit $5,850 And Below Before Full Recovery

Kiana Danial  |


Bitcoin has been under pressure along with many of its peers in the top 100 cryptos based on market cap. Its trading volume, on the other hand, continues to lead the market along with its market dominance. More companies are now accepting Bitcoin as a payment method than ever, and once we see the real bullish movement start again, we can expect to see more people jump back on the Bitcoin investing wagon. Until then, however, Bitcoin might drop back to 2018 lows and beyond based on some technical observations.

BTC/USD Technical Analysis

Looking at the daily chart you’d notice that BTC/USD has been forming lower highs since December 2017 when its bubble burst. Its key support level has remained below $6,000, at $5,850 to be precise. Each time its aimed to recover, its attempt has been capped at a lower resistance level than the time before. Hence the “lower highs.”

BTC/USD Daily Chart Technical Analysis - Lower Highs

BTC/USD Daily Chart Technical Analysis – Lower Highs

With the daily Ichimoku cloud flattening out, this could very well be the calm before a storm. But we still can’t say for sure that the storm will breakout to the upside first.

Analyzing the long-term pressure, you can argue that Bitcoin could revisit $5,850 once more. If its able to break below it, we might even see a revisit of $4,969 and $3,572. While our long-term outlook remains bullish on Bitcoin, market sentiment might not have Bitcoin’s back in the medium term. Now I’d like to hear from you. What do you think about Bitcoin’s future? How bullish or bearish are you on the cryptocurrency? Let me know in the comments, and subscribe for more updates!

As the 4th point of the IDDA technique, you must calculate your risk tolerance before deciding on the investment strategy that is suitable for your portfolio.

Don’t forget to complete your risk management due-diligence before developing your investment strategy.


Invest responsibly,

Kiana

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.